Summary Oestrogens and antioestrogens modulate the synthesis of transforming growth factor alpha (TGF-a) in breast cancer cells. The purpose of the present report was to examine regulation of TGF-a gene expression by oestradiol (E2) and antioestrogens in MDA-MB-231 breast cancer cells transfected with either the wild-type or mutant oestrogen receptor (ER). We recently reported the concentrationdependent E2 stimulation of TGF-a mRNA in MDA-MB-231 ER transfectants (Levenson et al, 1997) . We now report that 4-hydroxytamoxifen (4-OHT) shows oestrogen-like effects on the induction of TGF-a gene expression in our transfectants. Accumulation of TGF-a mRNA in response to both E2 and 4-OHT but not in response to the pure antioestrogen ICI 182,780 suggests that E2-ER and 4-OHT-ER complexes can bind to an oestrogen response element (ERE), located in the promoter region of the TGF-a gene and can activate transcription of the gene. Surprisingly, no activation of luciferase expression was observed after transient transfection of the TGF-a ERE/luciferase reporter constructs. Possible activation of an alternative ER-mediated pathway responsible for the regulation of TGF-a gene expression in the ER transfectants is discussed.
. The naturally occurring codon 351asp-tyr point mutation in the ligand-binding domain (LBD) of ER was identified in a tamoxifen-stimulated tumour line developed from MCF-7 breast cancer cells implanted into athymic nude mice (Wolf and Jordan, 1994a and b) . Our initial goal was to reassert hormonal control over hormone-independent breast cancer cells by transfecting the hER gene into cells lacking this protein (Jiang and Jordan, 1992) . During our investigation of the growth control mechanisms in the S30 cell line, we discovered that oestrogen causes an increase in the mRNA of transforming growth factor alpha (TGF-a) (Jeng et al, 1994) . The product can be easily measured by Northern blotting because the basal signal is already dramatically amplified in MDA-MB-23 1 cells.
The aim of this paper is to report progress in new investigations of TGF-a gene regulation by 17p-oestradiol (E2) and antioestrogens in S30 cells (wild-type ER) (Jiang and Jordan, 1992) and in BC-2 cells (codon 351asp-tyr mutant ER) .
Both S30 and BC-2 transfectants exhibit an E2 concentrationdependent induction of TGF-a mRNA expression (Levenson et al, 1997) . After an initial examination of the effects of keoxifene (raloxifene) on TGF-a mRNA in our transfectants when raloxifene exhibits oestrogen-like effects with mutant ER (BC-2 cells) but not with wild-type ER (S30 cells) (Levenson et al, 1997) , we were surprised to find that the potent tamoxifen metabolite 4-hydroxytamoxifen (4-OHT) (Jordan et al, 1977) produced an increase in TGF-a mRNA levels in a concentration-dependent manner in both cell lines. Thus both an oestrogen-and an antioestrogen-ER complex produce the same response at the same gene. The pure antioestrogen ICI 182,780 (Wakeling et al, 1991) , in contrast, can block the induction of TGF-x expression by E2 and 4-OHT in both cell lines. The observation that TGF-a mRNA is induced in response to both E2 and 4-OHT in both cell lines provides us with a powerful and unique model system in which to investigate the mechanism of how both E2 and 4-OHT can activate the same gene. As a first step in dissecting the signal transduction pathway of gene regulation, we took the direct approach of studying gene activation by E2 and 4-OHT through putative oestrogen response elements (EREs) located in the promoter region of the TGF-a gene (Saeki et al, 1991) . Unlike the consensus ERE, the putative EREs in the TGF-a promoter region were unable to activate a luciferase reporter gene in response to E2 or 4-OHT. These data suggest that an alternative, more complex mechanism must be available for ligands to initiate transcription of the TGF-ax gene.
MATERIALS AND METHODS Cell culture
The MDA-MB-231 cell line used was originally obtained from American Type Culture Collection (Rockville, MD, USA), and the clonal cell line (clone 1OA) was used for transfection of either wild-type ER cDNA (HEGO, S30 cells) (Jiang and Jordan, 1992) or codon 351asptyr mutant ER cDNA (HETO, BC-2 cells) . Cells were maintained in phenol red-free minimal essential medium (MEM) containing 5% charcoalstripped calf serum, penicillin (100 U ml-1), streptomycin (100 ,ug ml-), L-glutamine (2 mM), G-418 (500 ,ug ml-') , bovine insulin (6 ng ml-') and non-essential amino acids (100 mM). All materials were obtained from Gibco BRL, Life Technologies (Gaithersburg, MD, USA). Oestradiol was purchased from Sigma Chemical (St Louis, MO, USA), 4-OHT was a generous gift from Zeneca Pharmaceuticals (Macclesfield, UK) and ICI 182,780 was a generous gift from Dr Alan Wakeling (Zeneca Pharmaceuticals). All compounds were dissolved in 100% ethanol and added to the media in 1:1000 dilution for a final ethanol concentration no greater than 0.2%.
Northern blot analysis
Northern blot analysis was performed essentially as described previously (Levenson et al, 1997 One microgram of total RNA isolated from cells as described above was used in a reverse transcription reaction to obtain cDNA using the SuperScript Preamplification System for First Strand cDNA synthesis kit (Gibco BRL). Oligonucleotide primers were synthesized using published cDNA sequences for TGF-o (Tahara et al, 1995) and P2-microglobulin (P2-M) (Noonan et al, 1990 (1:2500 dilution) was added to the membrane and incubated for another 2 h at room temperature. The ECL Western blot detection reagents (Amersham, Buckinghamshire, UK) were used for visualization. The ECL detected blots were exposed to autoradiography film (Hyperfilm-ECL) for 1-5 min at room temperature.
Reporter gene constructs
The reporter construct pERE-Luc contains one Xenopus laevis vitellogenin A2 ERE (singlet ERE-luciferase), as has been described previously . We used the same pT109 luciferase plasmid (Nordeen, 1988) for constructs containing the putative TGF-a EREs. Oligonucleotides TGF-xl, TGF-a2, and TGF-adoublet (Figure 1 ), corresponding to the putative TGF-a EREs previously reported by Saeki et al (1991) , were synthesized to contain HindIII sites at each end. The oligonucleotides were annealed, phosphorylated and ligated into the Hindlll site of the pT109 luciferase plasmid (Nordeen, 1988) and transformed to E. coli DH5a cells. Individual colonies were chosen for plasmid preparation and restriction digestion to verify the presence of an insert. Plasmids containing inserts were sequenced to verify the correct sequence, orientation and to ensure the insertion of single and not multiple EREs. Two independent luciferase constructs were prepared for each TGF-al, TGF-a2 and TGF-odoublet EREs.
The plasmid pCMVP (Clonetech, Palo Alto, CA, USA), which contains the P-galactosidase gene, was used as an internal control for transient transfection efficiency in all experiments.
Transient transfection and luciferase assay MCF-7 and BC-2 cells were seeded in six-well plates at 5 x 105 cells per well in phenol red-free MEM media containing 5% charcoal-stripped calf serum as described above. Twenty-four hours (MCF-7) or 48 h (BC-2) later, the MCF-7 cells were transiently transfected using the calcium phosphate method , and the BC-2 cells using a liposome method (Campbell, 1995) . Each well of cells was co-transfected with 1.0 ,ug of the reporter-luciferase construct along with 0.5 jg of the pCMV-3-gal plasmid to normalize the transfection efficiency. After 4-6 h, the transfection mixture was removed and media containing compound(s) was added. As an intra-assay standard, a vitellogenin singlet ERE/luciferase reporter construct was transfected in parallel to serve as a comparison to each TGF-a-luciferase plasmid. Luciferase activity was measured 18-24 h later using a Monolight 2010 luminometer (Analytical Luminescence Laboratory), and 1-gal activity was assayed as in Luyten et al (1988) . Total luciferase units were divided by the total 1-gal units and expressed as a fold increase over the control (untreated = 1). The mean ± s.e. of at least three independent experiments performed in triplicate was graphed as a percentage of the maximum activity achieved with the vitellogenin ERE/luciferase construct.
British Journal of Cancer (1998) 77(11) We have previously demonstrated that there is a concentrationdependent induction of TGF-a mRNA by E2 in S30 (wild-type ER) and BC-2 (mutant ER) cells (Levenson et al, 1997) . We now examine the action of 4-OHT on the expression of the TGF-ax gene in these transfectants. The effect of 4-OHT on the expression of TGF-a mRNA in S30 and BC-2 cells was determined by Northern blot analyses 24 h after the addition of various concentrations of 4-OHT (Figure 2 ). Figure 2A shows that 4-OHT stimulates accumulation of TGF-a mRNA in S30 cells in a concentration-dependent manner. This agonist activity of the drug was unexpected because we and others had previously linked changes in the pharmacological properties of non-steroidal antioestrogens with mutations of the ER (Mahfoudi et al, 1995; Montano et al, 1996; Levenson et al, 1997) . Similar to the effect of 4-OHT seen in S30 cells (wild-type ER), there was a concentration-dependent induction of TGF-a mRNA in BC-2 cells, expressing mutant ER ( Figure 2B ). These results suggest that mechanisms other than mutation of the ER are responsible for the agonistic effect of 4-OHT on TGF-ax expression in these transfectants. Interestingly, the relative amount of TGF-a mRNA induced in BC-2 cells was more than twice that induced in the S30 (Figure 2 ). Our attempt to detect TGF-a mRNA in MCF-7 cells using total RNA in Northern blot were not successful because of the low abundance of transcripts. To illustrate the differences in the cell lines, we used semiquantitative RT-PCR to compare the effect of E2 and 4-OHT on TGF-ax mRNA expression in MCF-7, MDA-MB-231 and S-30 cells (Figure 3) . Our results show that (1) in MCF-7 cells TGF-a mRNA levels were increased by E2 (fivefold) but not by 4-OHT; (2) in MDA-MB-231 cells TGF-ax mRNA levels were unaffected by E2 treatment and were modestly reduced by 4-OHT; and (3) in S30 cells TGF-ax mRNA levels were increased by both E2 and 4-OHT by 9.5-and fourfold respectively. Although these data should be viewed as semiquantitative only, they do illustrate the differences in relative amounts of TGF-ac mRNA expression in different cell lines in response to E2 and 4-OHT. There is an apparent overexpression of TGF-a mRNA in response to both E2 and 4-OHT in S30 cells.
Regulation by oestradiol and antioestrogen
As both E2 and 4-OHT were able to stimulate TGF-a mRNA in S-30 and BC-2 cells, we decided to compare the potency of these two ligands. We performed Northern blot analyses of TGF-x mRNA expression using total RNAs from S30 cells treated with various concentrations of both compounds on the same membrane (Figure 4) . Both ligands had the same effect on TGF-ca mRNA levels at concentrations differing by three orders of magnitude (I0-9 M for E2 and I06 M for 4-OHT), indicating that E2 was more potent. Although 4-OHT acted as an agonist on TGF-a mRNA expression when added to cells alone, the possibility existed that 4-OHT and E2 would compete with each other for the ER to abolish TGF-a induction. However, the combined treatment of cells with E2 and 4-OHT did not alter TGF-a mRNA induction in either S30 or BC-2 cell lines, whereas the pure antioestrogen ICI 182,780 completely inhibited the action of E2 in both cell lines (data not shown).
Pure antioestrogen ICI 182,780 remains a complete antioestrogen and is able to block E2 and 4-OHT effects on TGF-a mRNA induction
The intriguing observation that the partial antioestrogen 4-OHT acts as a complete agonist in this model system prompted us to study the effect of other antioestrogens. We have recently reported the antagonistic action of raloxifene on TGF-ax mRNA induction in S30 (wild-type ER) cells compared with BC-2 cells expressing the mutant ER (Levenson et al, 1997) . Here, we expand our investigation and show that in S30 cells raloxifene blocked not only E2 action on the induction of TGF-a mRNA but also 4-OHT action ( Figure SA) . Pure antioestrogen ICI 182,780 blocked the action of E2 and 4-OHT in both cell lines as well as the agonistic action of raloxifene in BC-2 cells ( Figure SB and C) .
It is not clear whether stable integration of the transfected ER gene into chromosomal DNA might affect and alter the regulation of ER protein expression by E2 and antioestrogens (Levenson and Jordan, 1994) . The mechanism of action for pure antioestrogens (Wakeling and Bowler, 1988 ) is believed to result from the combined ability to reduce steady-state levels of the ER by increasing the turnover of the protein (Gibson et al, 1991; Dauvois et al, 1992) and to inhibit nucleocytoplasmic shuttling of the receptor by blocking its nuclear uptake (Dauvois et al, 1993) .
Therefore, it was of interest to examine the regulation of expression of the ER protein by E2 and antioestrogens in ER-transfected cells. Western blot analyses of whole-cell extracts from S30 and BC-2 cells treated with compound(s) for 24 h revealed an expected 66-kDa ER ( Figure 6 ). As seen in Figure 6A and B levels of ER protein were slightly down-regulated by E2, up-regulated by 4-OHT, not much altered by raloxifene and significantly decreased British Journal of Cancer (1998) (Pink and Jordan, 1996) .
Both E2 and 4-OHT do not activate the putative TGF-a EREs in a luciferase reporter plasmid Although E2 can increase the expression of TGF-a mRNA and can stimulate the production of TGF-x protein in breast cancer cells (Lippman et al, 1976; Salomon et al, 1989a and b) and E2-induced expression of TGF-a can be blocked by antioestrogens (Murphy and Dotzlaw, 1989) , it is not clear whether these effects of oestrogen are direct or indirect on stimulating transcription of the TGF-a gene. It has been suggested that two potential imperfect palindromic ERE-like sequences are present within the human TGF-a 5'-flanking sequence (Saeki et al, 1991) .
To investigate the mechanism of how E2 and 4-OHT can both activate the same gene we performed transient transfection experiments of luciferase reporter constructs containing each of the TGF-ax EREs separately, and in combination, retaining the 22-bp intervening sequence naturally found in the TGF-a promoter (Figure 1) . Initially, we used the MCF-7 cell line and then confirmed our observations using our transfectants. Figure 7A shows the results of transient transfection of these constructs into MCF-7 cells. There was no luciferase activity when cells were transfected with any of the 'TGF-aERE' constructs. Within the same assay a vitellogenin singlet ERE/luciferase reporter construct was used as a standard and was found to be activated by E2. Similar results were obtained in the T47D breast cancer cell line (data not shown). Figure 7B shows the results of transient transfection experiments of BC-2 cells, which are more easily transfectable than S30 cells. These results show that there is no activation of 'TGF-a EREs' by E2 at any concentrations and in fact there was only a very low activation of the singlet vitellogenin ERE construct. These data demonstrate that the putative TGF-a EREs in the promoter region are very weak and not sufficient alone to mediate either the E2 or the 4-OHT (data not shown) signal using our standardized reporter gene construct with a thymidine kinase (Tk) promoter.
DISCUSSION
Oestrogens are known to regulate the production of growth factors and their receptors in breast cancer (Lippman and Dickson, 1989) . It is well known that TGF-x mRNA and protein is induced by oestrogens in responsive breast cancer cells (Bates et al, 1988;  British Journal of Cancer (1998) 12 11 10 9 8 7 6
-log [Ml E2 Figure 7 The relative luciferase activity (normalized to ,-gal activity) of transiently transfected MCF-7 cells (A) and BC-2 cells (B) treated with a range of E2 concentrations. As an intra-assay standard, a vitellogenin singlet ERE/luciferase reporter construct was transfected in parallel to serve as a comparison to each TGF-a-luciferase plasmid. The results are expressed relative to the luciferase activities for the maximum fold-increase (over the untreated control) that was achieved with the vitellogenin ERE/luciferase construct for each experiment. The maximum fold-increase for the vitellogenin singlet differed between MCF-7 (50-fold) and BC-2 (threefold) and was assigned an arbitrary value of 100% for each cell line. The mean ± s.e.m. of at least three independent experiments performed in triplicate was graphed. -{-, Vitellogenin; -o-, TGF-a EREs Dickson et al, 1992) . The fact that this induction is mediated through the ER was supported by experiments with antioestrogens, which were able to block the induction caused by oestrogen (Murphy and Dotzlaw, 1989; Noguchi et al, 1993) . The mechanism of induction of TGF-a in cells is presumed to be direct, via the classical pathway in which the receptor binds to EREs in the promoter region of the gene as reported by Saeki et al (1991) .
In this report, we present the novel observation that endogenous TGF-a gene expression is stimulated by both E2 and 4-OHT in ER-negative breast cancer cells, stably transfected with either the wild-type (S30 cells) or the mutant ER (BC-2 cells). Thus both oestrogen-and antioestrogen-ER complexes produced the same response at the same gene in ER transfectants. These results were unexpected and suprising for two reasons: (1) tamoxifen is an antioestrogen in breast cancer cells with endogenous ER (MCF-7 cells, Figure 3 ), whereas it acts as an agonist in ER transfectants; (2) this agonistic activity of the drug was predictable with the mutant receptor but not with wild-type ER. Indeed, we have recently reported the antagonistic action of raloxifene on TGF-at mRNA induction in S30 (wild-type ER) cells compared with BC-2 cells (mutant ER) (Levenson et al, 1997) . We expanded our observation with raloxifene in this report and showed that raloxifene acted as an antagonist with wild-type ER and was able to block the effects of both E2 and 4-OHT in S30 cells ( Figure SA) .
The pure antiestrogen ICI 182,780 was able to block agonistic activities of E2 and 4-OHT in S30 cells and agonistic activities of all three ligands in BC-2 cells, remaining a complete antagonist with both wild-type and mutant ER ( Figure SB and C) . The explanation for the selective agonist/antagonist activity of partial antioestrogens in our model system is currently unclear. However, it is well known that the ligand-induced alterations in the conformation of the ER might be sensed by cellular factors (co-activators or/and co-repressors) that can mediate the activation functions of ER (Halachmi et al, 1994; Smith et al, 1997) . We think that identification of such accessory proteins may play a critical role in dissecting the signal transduction pathway in ER transfectants.
The observation that both wild-type and mutant ER did mediate the activation of the TGF-a gene in a similar manner suggests that the mutation in the LBD of the receptor does not affect the activation pathway qualitatively, although we noted quantitative differences (Figure 2 ). The ER level in both cell lines is quite high (BC-2 cells express a higher level of ER than S30) but similar to that in MCF-7 cells . We assume that in addition to the differences between transcription factor pools that interact with the ER in MCF-7 cells compared with parental MDA-MB-23 1, the different levels of ER in these cell lines might be responsible for the more intense induction of TGF-a in BC-2 cells compared with S30 cells (see Figure 2 ). We were not able to detect an E2-stimulated response of luciferase activity after transient transfections of the TGF-at ERE/luciferase reporter constructs. There are several explanations that may account for the inability to detect E2-stimulated luciferase expression in our MCF-7 cells. It is known that MCF-7 sublines differ in their degrees of responsiveness to E2 because of different levels of endogenous ER protein (Butler et al, 1986) . By manipulating the levels of ER one might be able to get a different response to E2. Recent data by El-Ashry et al (1996) demonstrated a 30-fold induction of chloramphenicol acetyltransferase (CAT) activity by oestrogen in MCF-7 cells supertransfected with a mouse ER expression vector and the putative TGF-a EREs cloned within the heterologous mouse mammary tumour virus (MMTV) promoter. However, in the absence of the exogenous mouse ER, oestrogen was not able to induce significant and reliable levels of CAT activity in MCF-7 cells, neither with its own TGF-a promoter nor with the TGF-x EREs cloned within the MMTV promoter (EI-Ashry et al, 1996) . Similarly, in our experiments with a reporter plasmid containing the entire promoter region of the TGF-a gene (pTGF-a-2813Luc, generously provided by Dr D Salomon, NIH, Bethesda, MD, USA), we did not observe induction of luciferase activity in oestrogen-treated MCF-7 cells. We did, however, detect very weak transcriptional activation with both E2 and 4-OHT in BC-2 cells, although the results were variable and inconsistent (data not shown). Thus, our results are in agreement with those of El-Ashry et al (1996) in terms of the inability of the TGF-a promoter and TGF-a EREs to mediate a significant response in MCF-7 cells not boosted with exogenous ER. The discrepancy between our results and those of El-Ashry et al (1996) might be due to differences in the transfected cell lines used (they used MCF-7 and Cos-7 cells transfected with mouse ER, whereas we used a different subline of MCF-7 cells not transfected with exogenous ER and MDA-MB-231 transfected with human ER), and/or in the nature of heterologous promoter used in the reporter constructs (they used MMTV, whereas we used Tk). Finally, consistent with our results, Saeki et al (1991) reported that a fragment that just contained the putative ERE-like elements (pTGF-at37OLuc) was very weak and that additional cis-acting elements might be involved in amplifying the effects of E2 in MCF-7 cells.
Both E2 and 4-OHT failed to activate putative TGF-a EREs in MCF-7 and BC-2 cells, suggesting that a pathway other than the classical ERE pathway may be contributing to the induction of the TGF-a gene in these cells. Activation of the activating protein-I (AP-1) mediated pathway by the ER-ligand complex has been reported as an alternative pathway for ER action in breast cancer cells after long-term tamoxifen treatment (Astruc et al, 1995) as well as in other cell lines (Gaub et al, 1990; Philips et al, 1993; Umayahara et al, 1994; Webb et al, 1995) . It is possible that as a consequence of transfection of the ER into cells that were initially ER negative, the classical ER-mediated pathway is shifted towards the alternate pathway.
In summary, we have shown that 4-OHT produces oestrogenlike effects on the induction of TGF-a gene expression in ER transfectants. The observation that the TGF-ax gene is activated by both E2 and 4-OHT in breast cancer cells is unique, as in the Ishikawa human endometrial carcinoma cell line in which activation of several genes by both E2 and 4-OHT is reported (Albert et al, 1990; Sundstrom et al, 1990; Jamil et al, 1991; Huynh and Pollak, 1993) , TGF-x expression is up-regulated by E2 but not by 4-OHT (Gong et al, 1992) . We have, therefore, defined a novel system to test the biochemical mechanism whereby an oestrogen-and an antioestrogen-ER complex can induce the same gene in breast cancer cells. The presented data suggest that there are additional factors present in MDA-MB-231 cells that facilitate gene activation by both an oestrogen-and antioestrogen-receptor complex. These factors may allow the antioestrogen-ER complex to be promiscuous if the ER is overexpressed. We are in the process of dissecting this signal transduction pathway that may suggest a mechanism for the target site-specificity of antioestrogens. ABBREVIATIONS ER, oestrogen receptor; LBD, ligand binding domain; ERE, oestrogen response element; TGF-a, transforming growth factor alpha; E2, 17p-oestradiol; 4-OHT, 4-hydroxytamoxifen; AP-1, activating protein-i; CAT, chloramphenicol acetyltransferase; P2-M, [B2-microglobulin; Tk, thymidine kinase; MMTV, mouse mammary tumour virus; RT-PCR, reverse transcriptase-polymerase chain reaction; PBS, phosphate-buffered saline.
